The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease
Open accessAbstract
OBJECTIVE: To determine the frequency and correlates of impulse control disorders (ICDs) in Parkinson disease (PD). DESIGN: An unstructured screening interview for ICDs (compulsive gambling, buying, and sexual behavior) followed by a telephone-administered structured interview for screen-positive patients. SETTING: Two university-affiliated movement disorders centers. PARTICIPANTS: A convenience sample of 272 patients with idiopathic PD who were screened for psychiatric complications. MAIN OUTCOME MEASURES: Presence of compulsive gambling, buying, or sexual behavior as assessed by the Minnesota Impulsive Disorders Interview. RESULTS: Eighteen patients (6.6%) with PD met criteria for an ICD at some point during the course of PD, including 11 (4.0%) with an active ICD. Compulsive gambling and compulsive sexual behavior were equally common. In a multivariate model, treatment with a dopamine agonist (P = .01) and a history of ICD symptoms prior to PD onset (P = .02) predicted current ICD. There were no differences between the dopamine agonists in their association with ICDs (P = .21), and daily doses of dopamine agonists were higher in patients with an ICD than in dopamine agonist-treated patients without an ICD (P < .001). CONCLUSIONS: Patients with PD treated with a dopamine agonist should be made aware of the risk of developing an ICD and monitored clinically. Because dopamine agonists are increasingly being used for other indications, future research should assess the dopamine agonist-associated risk for ICDs in other populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“impulse-control disorder (ICD) development in PD patients has been associated with dopamine agonist pharmacotherapy (Weintraub et al., 2006”
From Remote delivery of psychological interventions for Parkinson's disease. (2018) · cites this paper as Weintraub et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
An algorithm (decision tree) for the management of Parkinson’s disease (2001):
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 724
Compulsive buying: descriptive characteristics and psychiatric comorbidity.
Ga, C., Faber, R., de Zwaan, M., Raymond, N. C., Sm, S., Ekern, Tb, M., Crosby, R. D., Sj, C., & Ed, E. (1994) · PubMed · Cited by 664
Giovannoni, G. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.4.423 · Cited by 587
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Dodd, M. L., Klos, K. J., Bower, J. H., Geda, Y. E., Josephs, K. A., & Ahlskog, J. E. (2005) · Archives of Neurology · doi:10.1001/archneur.62.9.noc50009 · Cited by 563
Flagged first, then by citations
Research works printed but not linked: 2
- [4]American Psychiatric Association. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000. Diagnostic and Statistical Manual of Mental Disorders. [Google Scholar]
- [6]Tyne HL, Medley G, Ghadiali E, Steigner MJ. Gambling in Parkinson’s disease. Movement Disorders. 2004;19(suppl 9):S195. [Google Scholar]
Cited by
Sorted by citations
Items 601–661 of 661
Pérez‐Neri, I. (2016) · Archivos de Neurociencias · doi:10.31157/an.v21i4.139
The Prevalence of sexual dysfunction in Parkinson's Disease
Çağaç, A., Gül, A., Milanlıoğlu, A., & Çilingir, V. (2021) · Van Medical Journal · doi:10.5505/vtd.2021.37974
“Dopamin agonisti kullanan PH’da % 3,5'inde - % 8,8 oranında cinsel dürtüde artış olduğu bildirilmiştir (23,24).”
Discontinuation of Dopamine Agonists in Parkinson’s Disease: A Retrospective Analysis
Çelik, N. D., Kuzu, M., Aykaç, Ö., & Özkan, S. (2021) · OSMANGAZİ JOURNAL OF MEDICINE · doi:10.20515/otd.943133
Approche épidémiologique et évaluative des comportements addictifs
de Chazeron, I. (2009) · HAL
Parkinson's disease and Behavioural Addiction: The susceptibilities and risks
Sharma, M. K., Amudhan, S., Anand, N., Mukadam, A., Sinha, M., Thakur, P. C., Tadpatrikar, A., & Manaria, S. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102960
Schnitzler, A., & Pollok, B. (2010) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.2768957.2434055
Hurwitz, T. D., Schenck, C. H., & Khawaja, I. S. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_37
Jenkins, M. E., Miyasaki, J. M., & Suchowersky, O. (2011) · Springer eBooks · doi:10.1007/978-0-387-88555-1_7
(2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815002-3.00020-6
Nonmotor problems in Parkinson disease
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C. L., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00008-1
Ceballos-Baumann, A., Schwarz, M., Wessel, K., & Weiland, T. (2011) · Springer eBooks · doi:10.1007/978-3-642-16920-5_41
KMT5B is differentially expressed in the brains of patients with Parkinson’s Disease.Preprint
Mamoor, S. (2020) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/vg4zh
Antonini, A. (2011) · doi:10.1007/978-1-908517-60-9_9
Pargeon, K. L., Anderson, K. E., & Weiner, W. J. (2011) · Parkinson s Disease · doi:10.1002/9781444397970.ch27
Shih, L. C., & Tarsy, D. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50048-2
Hurwitz, T. D., & Schenck, C. H. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-252-6_37
ANK1 is differentially expressed in the brains of patients with Parkinson’s Disease.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/efnzh
Ataniya, R., Koike, K., & Inamoto, A. (2022) · Research Square · doi:10.21203/rs.3.rs-1699376/v1
Siebner, H. R., & Herz, D. M. (2013) · Springer eBooks · doi:10.1007/978-3-642-34342-1_18
Wexler, T., & Page‐Wilson, G. (2022) · doi:10.22541/au.166746244.47678512/v1
Szarpak, J., Drożak, P., Piwoński, M., Wróblewski, H., & Morylowska-Topolska, J. (2022) · Current Problems of Psychiatry · doi:10.2478/cpp-2022-0021
Behavioral disturbances in Parkinson's disease patients receiving dopaminergic therapy
Nikitina, A. V., & Fedorova, N. V. (2017) · Annals of Clinical and Experimental Neurology · doi:10.17816/acen.2017.1.6149
Stimolazione cerebrale e malattia di Parkinson
Guehl, D., Burbaud, P., Courtin, E., Cuny, E., & Damon‐Perrière, N. (2023) · EMC - Neurologia · doi:10.1016/s1634-7072(23)47685-4
Edible Bird’s Nest: Seeing the Unseen
Mohamed, W. M. Y. (2023) · Nutritional neurosciences · doi:10.1007/978-981-99-1513-2_6
Juarez, L. G. L., Garcia, A., Rodríguez‐Violante, M., Cervantes‐Arriaga, A., Cruz, E. C. S. D. L., Delgado, M., Hernandez-Medrano, A. J., Regalado-Mustafá, A. Y., & Patlan, G. E. D. L. R. (2023) · Archivos de Neurociencias · doi:10.31157/an.v1iinpress.652
Bentabet, F., Elmansouri, H., Adali, I., & Manoudi, F. (2024) · Scholars Journal of Medical Case Reports · doi:10.36347/sjmcr.2024.v12i04.038
Disruptive, Impulse-Control, and Conduct Disorders
Bains, A., & Sanders, K. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11844-9.00023-0
Current Treatments for Schizophrenia
GOFF, D. C. (2025) · doi:10.1093/med/9780197640654.003.0018
Exploring the link between personality dimensions and non-motor fluctuations in Parkinson's disease
Boussac, M., Faggianelli, F., Harroch, E., Eusébio, A., Fabbri, M., Ory‐Magne, F., Descamps, É., Rascol, O., Laurencin, C., Marquès, A., et al. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251354932
“26,36 37 – 39 Novelty seeking is a major predictor of impulsive and addictive behaviors.”
Cognitive structure and progression in Parkinson’s disease: insights from a tablet-based assessment
Feige, T., Frank, A. K., Bendig, J., Epler, A., Harbarth, C., Kunze, J., Jungk, J., Schnalke, N., Reichmann, H., & Falkenburger, B. H. (2026) · Scientific Reports · doi:10.1038/s41598-026-62324-6
“Dopamine agonists increase reflection impulsivity 63 and all dopaminergic treatment can cause impulse-control disorders 64–66 .”
Papadopetraki, D., Cools, R., Taylor, K. I., Popp, W., Siderowf, A. D., Weintraub, D. A., & Kurniawan, I. T. (2025) · doi:10.2196/preprints.81913
Self-citationMartinez, J. D., & Barragán, J. A. (2013) · Aaltodoc (Aalto University)
Behavioral Pharmacology of Dopamine D2 and D3 Receptor Agonists and Antagonists in Rats.
Collins, G. T. (2008) · Deep Blue (University of Michigan)
Lundström, H., Berglund, T., & Lycke, S. (2014) · Uppsala University Publications (Uppsala University)
Xiao, Y., Kang, S., Ou, R., Lin, J., Yang, T., Jiang, Q., Song, W., & Shang, H. (2026) · Neurological Sciences · doi:10.1007/s10072-025-08631-8
Mo, F., Cheng, T., Kong, Y., Wu, K., Liang, Z., Yang, B., Li, J., Liu, T., Chen, C., Yang, H., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8883462/v1
Maladie de Parkinson et trouble du contrôle des impulsions
Rousvoal, K., & Corvol, J.-C. (2026) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(25)50185-9
Carrière, N. (2015) · theses.fr (ABES) · doi:10.70675/08ca0910za340z4a0bzaf66z1be41e77e43e
Boussac, M. (2021) · theses.fr (ABES) · doi:10.70675/f0a1096dze299z4436zb794zc2a019a7b46a
The neurobiology of normal and pathological prior beliefs during cognitive control
Rondot, L. (2020) · theses.fr (ABES) · doi:10.70675/de55dc43ze329z41adz92f4z21076f73ccf6
Mental health, climate anxiety, and progression of Parkinson’s disease
Lau, Y. H., Popławska-Domaszewicz, K., Haridas, S., Chopra, S., Koh, K. L., & Chaudhuri, К. R. (2026) · International review of movement disorders · doi:10.1016/bs.irmvd.2026.03.003
Bases neuro-fonctionnelles des troubles de l’impulsivité dans la maladie de Parkinson
Meyer, G. M. (2022) · theses.fr (ABES) · doi:10.70675/ebcaf07cz9890z4e15zb160z1746f591e65c
Staubo, S. C., Størset, E., Toft, M., Lie, I. H., Alvik, K. M. J., Jostad, P., Tingvoll, S. H., Rosqvist, K., Odin, P., Dietrichs, E. S., et al. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1791205
“The association between dopamine agonists and impulse control disorders was first published in 2006 (3), several years after non-ergot dopamine agonists were introduced to treat motor symptoms in people with PD (4).”
Papadopetraki, D., Cools, R., Taylor, K. I., Popp, W., Siderowf, A. D., Weintraub, D. A., & Kurniawan, I. T. (2025) · JMIR Formative Research · doi:10.2196/81913
Self-citationMalattia di Parkinson e disturbo del controllo degli impulsi
Rousvoal, K., & Corvol, J.-C. (2026) · EMC - Neurologia · doi:10.1016/s1634-7072(26)51985-8
Whitaker, G. A., Poliakoff, E., Martin, S. L., Neill, J. C., Silverdale, M., Kobylecki, C., & El‐Deredy, W. (2026) · Experimental Brain Research · doi:10.1007/s00221-026-07355-1
“This is thought to be caused by non-selective effects of dopamine drugs on different brain systems, as well as individual dif - ferences in patients' dopamine systems (Napier et al. 2015; Weintraub et al. 2006).”
Mecheri, Y. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27702-3.00026-1
Salience attribution in addiction and psychosis
Freeman, T. P. (2013) · UCL Discovery (University College London)
Lima, Á. M. A. (2009) · DOAJ (DOAJ: Directory of Open Access Journals)
Alteracoes Neuropsiquiatricas da Doenca de Parkinson
Peixinho, A. T., Azevedo, A., & Simões, R. M. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · doi:10.25752/psi.6037
Estimulación dopaminérgica en los trastornos no motores de la enfermedad de Parkinson
Pueyo, Á. M., Izquierdo, N. B., Sanz, A. C., & Vico, J. R. (2010) · Revista de Neurología · doi:10.33588/rn.50s02.2009744
NEUROPROTECTIVE STUDIES ON THE MPTP AND SOD1 MOUSE MODELS OF NEURODEGENERATIVE DISEASES
Fontanilla, C. V. (2012) · IUScholarWorks (Indiana University) · doi:10.7912/c2/2043
Metadata
- Authors
- Weintraub, D., Siderowf, A. D., Potenza, M. N., Goveas, J., Morales, K. H., Duda, J. E., Moberg, P. J., & Stern, M. B.
- Affiliations
- University of Pennsylvania (US)
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2006-07-01
- Volume
- 63
- Issue
- 7
- Pages
- 969
- ISSN
- 0003-9942 (ISSN-L)
- PMC
- PMC1761054
- OpenAlex
- W2035890213
- Cited by
- 662
- References
- 17
- Citations by year
- 2026: 14 · 2025: 13 · 2024: 12 · 2023: 16 · 2022: 18 · 2021: 18 · 2020: 36 · 2019: 38 · 2018: 23 · 2017: 32 · 2016: 40 · 2015: 26 · 2014: 40 · 2013: 45 · 2012: 40
- FWCI
- 30.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (K23MH067894)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Social Sciences › Psychology › Clinical Psychology › Gambling Behavior and Treatments
- Keywords
- Parkinson's disease, impulse control disorders, dopamine agonists, gambling addiction, compulsive buying, compulsive sexual behavior, psychiatric complications, adverse drug reactions, risk factors, dose-response relationship
- MeSH terms
- Pramipexole, Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Gambling, Humans, Disruptive, Impulse Control, and Conduct Disorders, Indoles, Male, Middle Aged, Parkinson Disease, Pergolide, Risk Factors, Sexual Behavior, Sexual Dysfunction, Physiological, Thiazoles, Logistic Models, Dopamine Agonists, Benzothiazoles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
